Users
This article provides detailed stock information for LENZ Therapeutics, Inc. (LENZ), including its current quote, performance metrics, and a list of recent news and press releases. It covers financial results, corporate highlights, product submissions for approval, and investor alerts from various sources. The stock closed at 7.340 with a slight uptick, despite significant year-to-date and long-term declines.
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Analysts have significantly revised down their forecasts for LENZ Therapeutics, Inc. (NASDAQ:LENZ) for 2026, cutting revenue estimates and increasing projected losses per share. The new consensus from seven analysts anticipates revenues of US$19 million and a loss of US$4.50 per share, leading to a 19% reduction in the consensus price target to US$32.00. This downgrade suggests growing caution among investors regarding the company's future valuation and performance.
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Analysts have significantly revised down their forecasts for LENZ Therapeutics, Inc. for the coming year. Revenue estimates for 2026 were cut to US$19 million, reflecting a 9.3% reduction, and per-share losses are now expected to reach US$4.50. This downgrade has also led to a 19% reduction in the consensus price target to US$32.00.
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
LENZ Therapeutics, Inc. (NASDAQ:LENZ) recently reported quarterly results, with revenues beating expectations but statutory losses per share increasing significantly. Following these results, analysts have made serious cuts to their revenue outlook for 2026, forecasting a 4.5% reduction in revenue and a 29% increase in losses per share. This led to a 15% drop in the average price target, reflecting concerns about the company's future valuation and performance.
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates
LENZ Therapeutics, Inc. (LENZ) announced a wider-than-expected loss for the fourth quarter, reporting a loss of 69 cents per share. The company also reported no revenue for the period, falling short of analyst estimates. This performance suggests challenges for LENZ Therapeutics as it moves forward.
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
LENZ Therapeutics, Inc. reported quarterly results showing revenues of US$1.9m, beating expectations, but statutory losses per share increased to US$1.32. Following these results, analysts have significantly cut revenue forecasts for 2026 to US$20.0m and increased loss per share estimates to US$4.47, leading to a 15% reduction in the average price target to US$33.71. The adjustment reflects concerns about future performance despite exceeding revenue expectations this quarter.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
LENZ Therapeutics' shares have suffered a significant drop following its latest quarterly results, leading analysts to revise their earnings forecasts downwards. The consensus estimates suggest a substantial increase in losses for the current financial year and potentially the next, with revenue expectations also seeing a decrease. Despite the share price slump, one analyst has recently reiterated a "Buy" rating, indicating some continued optimism for the company.
LENZ Therapeutics Company Profile & Introduction
This article provides a company profile and introduction for LENZ Therapeutics.
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales By Investing.com
Piper Sandler downgraded LENZ Therapeutics Inc. to Neutral from Overweight and lowered its price target to $12.00 from $39.00 due to a slower-than-expected sales trajectory for their VIZZ product. This action follows LENZ's Q1 2026 earnings report, which showed revenues of $1.9 million, but highlighted concerns about the pace of new patient starts and routine prescribing, despite an increase in prescriptions. Although the company is quickly burning through cash, InvestingPro analysis indicates the stock may be undervalued at current levels.
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating
William Blair analyst Lachlan Hanbury Brown has maintained a Buy rating for LENZ Therapeutics (LENZ.US). The analyst has a 36.6% success rate and a 2.5% average return over the past year, according to TipRanks data. This information is for informational purposes only and does not constitute investment advice.
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield reduced the price target for Lenz Therapeutics (LENZ) to $38 from $48 while maintaining a Buy rating on the shares. This adjustment reflects a lowered estimate for 2034 peak penetration for the VIZZ launch, from 30% to 25%.
LENZ Therapeutics stock price target lowered to $38 by H.C. Wainwright
H.C. Wainwright lowered its price target for LENZ Therapeutics (NASDAQ:LENZ) to $38 from $48, while maintaining a Buy rating. This adjustment follows the broad launch of VIZZ, a presbyopia eye drop, with analysts anticipating a multi-quarter trajectory for market penetration. Despite the lowered target, the firm notes the stock appears undervalued, though it acknowledges the company's high cash burn rate due to commercial expansion.
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales
Piper Sandler downgraded LENZ Therapeutics (NASDAQ:LENZ) to Neutral from Overweight and reduced its price target to $12.00 from $39.00 due to slower-than-expected sales of its VIZZ product. Despite a 19% increase in prescriptions, the company is still burning cash, leading to the rating cut, though some analysis suggests the stock might be undervalued. LENZ is implementing strategies to boost VIZZ adoption, including in-office dispensing and direct-to-consumer messaging.
Lenz Therapeutics Releases 2026 First Quarter Results
Lenz Therapeutics reported its Q1 2026 financial results, showing $1.9 million in total revenue, primarily from VIZZ product sales. VIZZ, an FDA-approved eye drop for presbyopia launched in October 2025, saw nearly 25,000 paid prescriptions in the quarter. The company's cash position was $258.4 million, and it anticipates funding operations to post-launch positive cash flow.
LENZ Therapeutics (LENZ) ramps VIZZ launch with higher Q1 2026 losses
LENZ Therapeutics reported $1.9 million in total revenue for Q1 2026, primarily from initial VIZZ product sales and license revenue, marking its first quarter of significant commercial activity. The company incurred a net loss of $41.5 million due to substantial increases in selling, general, and administrative expenses related to the U.S. launch and marketing of VIZZ, while research and development costs declined to zero following FDA approval. LENZ ended the quarter with $258.4 million in cash, cash equivalents, and marketable securities, which the company believes will be sufficient to fund operations to positive operating cash flow.
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics reported Q1 2026 results, showing continued growth for its presbyopia eye drop VIZZ, though new patient adoption is slower than anticipated. Management is focusing on increasing physician adoption through consistent prescribing during routine eye exams and targeting contact lens wearers, as well as refining direct-to-consumer messaging. The company also detailed its financial performance, commercial strategy, safety profile of VIZZ, and plans for global expansion.
Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)
Lenz Therapeutics (LENZ) announced its Q1 results, reporting an EPS of ($1.32) against a consensus of ($1.07) and revenue of $1.9M, exceeding the consensus of $1.76M. President and CEO Eef Schimmelpennink highlighted significant progress in the VIZZ launch, including high ECP awareness, growing prescriber confidence, and early positive refill dynamics, reinforcing confidence in the long-term opportunity for their presbyopia treatment. The company aims to further integrate VIZZ into practices and drive adoption of this new treatment category.
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates
LENZ Therapeutics, Inc. (LENZ) announced its first-quarter 2024 financial results, reporting a loss of $0.94 per share. Despite the loss, the company surpassed revenue estimates, posting $6.4 million against an expected $3.5 million. This financial update provides investors with key performance indicators for the recent quarter.
LENZ: Q1 2026 saw VIZZ's commercial launch, $1.9M revenue, and a $41.5M net loss amid rapid expansion
LENZ Therapeutics reported $1.9M in Q1 2026 revenue from the commercial launch of VIZZ, an FDA-approved eye drop for presbyopia. Despite the revenue, the company posted a $41.5M net loss due to high commercialization costs. With $258.4M in cash reserves, LENZ anticipates funding operations to positive cash flow while navigating international expansion and market risks.
Sarah Jessica Parker backs presbyopia drops as LENZ fills 46k scripts
LENZ Therapeutics reported Q1 2026 revenue of $1.9 million, with $1.7 million from VIZZ sales and approximately 46,000 prescriptions filled since launch, involving over 10,000 eye care professionals. The company launched a direct-to-consumer campaign with Sarah Jessica Parker and is expanding its sales force while pursuing international market authorizations. Despite these advancements, LENZ recorded a net loss of $41.5 million in Q1 2026, and its stock experienced a negative reaction post-announcement, consistent with past earning patterns.
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its first quarter 2026 financial results, with total revenue of $1.9 million, including $1.7 million from VIZZ product sales. The company has seen broad uptake of its VIZZ eye drops for presbyopia, with approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals since launch. LENZ is expanding its sales force and has launched a direct-to-consumer campaign featuring Sarah Jessica Parker to drive further awareness and adoption.
Number of shareholders of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides the title for information regarding the number of shareholders of LENZ Therapeutics, Inc. (NASDAQ: LENZ) on the TradingView platform. It appears to be a stub or a section of a larger financial data representation, with placeholders for 'Period', 'Value', 'Change', and 'Change %' related to shareholder data. The content primarily consists of navigation links and copyright information for the TradingView website.
LENZ adds Bank of America meetings after May 11 results call
LENZ Therapeutics announced it will report its first-quarter 2026 financial results and corporate highlights via a live webcast on May 11, 2026, at 4:30 p.m. EDT. Following this, the company's management will hold one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026, in Las Vegas. LENZ commercializes VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for presbyopia.
Press Release: LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics will release its first quarter 2026 financial results on Monday, May 11, 2026, after market close. The company will also host a conference call and webcast on the same day to discuss these results and provide corporate updates. Additionally, LENZ Therapeutics plans to present at the Bank of America Healthcare Conference on May 15, 2026.
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics announced it will report its first quarter 2026 financial results and recent corporate highlights on May 11, 2026, via a webcast. The company will also participate in one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026. LENZ Therapeutics focuses on commercializing VIZZ® (aceclidine ophthalmologic solution) for presbyopia.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12%
Analysts have significantly revised down their revenue forecasts for LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 12% for 2026, now predicting US$25m, alongside an increase in expected per-share losses to US$3.99. Despite the downgrade, the company's projected 30% annual revenue growth is still expected to outpace the wider pharmaceutical industry's 8.6% growth. This change in sentiment may lead to increased caution among investors.
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $29
BofA Securities analyst Jason Gerberry has reiterated a Buy rating for LENZ Therapeutics (LENZ.US) and maintained a target price of $29. This analyst has a strong track record, with a 60.5% success rate and an average return of 17.9% over the past year, according to TipRanks data. The information is provided for informational purposes and is not an investment recommendation.
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday
LENZ Therapeutics (LENZ) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts forecasting EPS of ($1.05) and revenue of $2.202 million. The company missed prior quarter estimates, and analysts now project negative EPS for the current and next fiscal year. Despite recent price target cuts, the stock currently holds a "Moderate Buy" consensus rating with an average price target of $44.
[ARS] LENZ Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by LENZ Therapeutics, Inc. The filing was made on April 28, 2026, and is available as a PDF document. The article also provides a brief overview of LENZ Therapeutics, including its market capitalization, recent news, and other SEC filings.
Board elections and auditor vote at LENZ (NASDAQ: LENZ) 2026 virtual meeting
LENZ Therapeutics will hold its 2026 virtual annual stockholder meeting on June 12, 2026, where shareholders will vote on the election of three Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board recommends voting "FOR" all director nominees and the auditor ratification. The proxy statement details board composition, governance policies, and executive and director compensation, including CEO Evert Schimmelpennink's 2025 compensation totaling over $7 million.
BlackRock (LENZ) discloses 1,804,099 shares, 5.8% stake (Schedule 13G)
BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 1,804,099 shares, or a 5.8% stake, in Lenz Therapeutics (LENZ) as of March 31, 2026. This filing indicates that BlackRock holds sole voting power over 1,782,990 shares and sole dispositive power over all 1,804,099 shares. The disclosure is considered a passive institutional holding, which does not suggest an intent to influence or change control of the issuer.
LENZ Therapeutics submits MAA for Vizz to UK’s Medicines and Healthcare Products Regulatory Agency
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) for Vizz (aceclidine ophthalmic solution) 1.44% to the UK’s Medicines and Healthcare Products Regulatory Agency. Vizz is an eye drop for treating presbyopia in adults and this is LENZ Therapeutics sixth regulatory filing outside the US after FDA approval in July 2025. The application is supported by data from three randomized, double-masked, controlled Phase 3 CLARITY trials, which showed significant improvement in near vision lasting up to 10 hours with no serious treatment-related adverse events.
HC Wainwright Expects Weaker Earnings for LENZ Therapeutics
HC Wainwright has lowered its Q1 2026 EPS estimate for LENZ Therapeutics to ($1.11) from ($0.86) and projects a full-year 2026 loss of ($3.89), while maintaining a "Buy" rating and a $48 price target. The company reported a Q1 EPS loss of ($1.16) and revenue of $1.59 million, both below analyst expectations. Despite a consensus target price of $44 among analysts, LENZ shares are currently trading around $9.99, significantly below their 52-week high of $50.40.
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates
LENZ Therapeutics, Inc. reported a Q4 loss, failing to meet revenue estimates. This financial update indicates the company's performance during the fourth quarter fell short of market expectations, particularly on the revenue front.
LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into LENZ Therapeutics, Inc. (NASDAQ: LENZ) for potential securities fraud following a significant drop in its stock price. This decline occurred after safety data emerged regarding the company's VIZZ eye drop, specifically a reported retinal tear, which led to a substantial loss of investor confidence and an erosion of shareholder value. The firm is encouraging affected investors to contact them to discuss their legal rights and potential class action.
Lenz Therapeutics stock price target cut to $48 by H.C. Wainwright
H.C. Wainwright has reduced its price target for Lenz Therapeutics Inc. (NASDAQ:LENZ) to $48 from $56, while maintaining a Buy rating. This adjustment comes ahead of the company's Q1 2026 earnings and is based on tightened expectations for the launch of its presbyopia eye drop, VIZZ, which began sample availability in October 2025 and a broader launch in late 2025. Despite the lowered target, the firm continues to be optimistic about VIZZ's adoption growth and the stock's potential upside, noting it trades below its Fair Value.
LENZ Maintained by HC Wainwright & Co. -- Price Target Lowered t
LENZ Therapeutics received a maintained 'Buy' rating from HC Wainwright & Co., though the price target was lowered from $56.00 to $48.00. The company's GF Score is 22/100, indicating challenges in profitability despite financial stability, and insiders have shown confidence with $0.4 million in recent stock purchases.
Lenz Therapeutics stock price target cut to $48 by H.C. Wainwright
H.C. Wainwright has lowered its price target for Lenz Therapeutics (NASDAQ:LENZ) to $48 from $56, while maintaining a Buy rating. The adjustment comes ahead of the company's first-quarter 2026 earnings report, which will reflect the initial full period of sales for VIZZ, a topical presbyopia eye drop. Despite the reduced target, the firm continues to see significant upside from the current stock price, driven by the real-world performance of VIZZ.
LENZ submits UK application for presbyopia eye drop VIZZ
LENZ Therapeutics, Inc. has submitted a Marketing Authorization Application to the UK's Medicines and Healthcare products Regulatory Agency for its presbyopia eye drop, VIZZ. This marks the sixth international regulatory filing for the treatment, which received U.S. FDA approval in July 2025 and has also been submitted to the European Medicines Agency. The application is supported by positive Phase 3 clinical trial data showing rapid and lasting improvement in near vision with manageable side effects.
LENZ submits UK application for presbyopia eye drop VIZZ By Investing.com
LENZ Therapeutics has submitted a Marketing Authorization Application to the UK's Medicines and Healthcare products Regulatory Agency for its presbyopia eye drop, VIZZ. This is the sixth international regulatory filing for VIZZ, which has already received U.S. FDA approval. The eye drop is designed to treat age-related blurry near vision and showed promising results in clinical trials without serious adverse events.
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the UK's MHRA for VIZZ® (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This submission marks the sixth ex-U.S. regulatory filing for VIZZ, following its FDA approval in July 2025 and an MAA submission to the EMA. The company aims for broad international expansion and commercialization across Europe.
LENZ submits UK application for presbyopia eye drop VIZZ By Investing.com
LENZ Therapeutics, Inc. has submitted a Marketing Authorization Application to the UK's Medicines and Healthcare products Regulatory Agency for its presbyopia eye drop, VIZZ. This marks the sixth international regulatory filing for the treatment, which received U.S. FDA approval in July 2025. VIZZ is designed to treat age-related blurry near vision, with clinical trials demonstrating rapid and sustained improvement.
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the UK's MHRA for VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia. This marks the sixth ex-U.S. regulatory submission for VIZZ, expanding its global reach following FDA approval in July 2025. The submission is supported by positive Phase 3 CLARITY trials showing VIZZ's effectiveness in improving near vision for up to 10 hours and good tolerability.
Aging-eye drop heads to UK review as 20M adults face presbyopia
LENZ Therapeutics has submitted a Marketing Authorization Application for its VIZZ® (aceclidine 1.44%) eye drop to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of presbyopia. This marks the sixth ex-U.S. regulatory submission for VIZZ, following FDA approval in July 2025. The application is supported by positive data from three Phase 3 CLARITY trials, which showed that VIZZ improved near vision within 30 minutes for up to 10 hours with no serious treatment-related adverse events.
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10
The article reports that the price target for LENZ Therapeutics (LENZ) has been decreased by 20.47%, bringing it down to $39.10. No further details are provided in the current content.
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ)
This article provides a detailed overview of LENZ Therapeutics Inc. (NASDAQ: LENZ) stock performance, technical and fundamental analysis, and key financial data. As of April 13, 2026, LENZ was trading at 9.63 USD, up 6.17% for the day. Analysts predict a significant price increase of 306.02% in the next year, with an average price target of 39.1 USD, despite recent misses in EPS and revenue expectations.
Squarepoint entities hold multiple 5% stakes in LENZ (NASDAQ: LENZ)
Multiple Squarepoint entities have reported holding various beneficial ownership stakes in LENZ Therapeutics, Inc. According to a Schedule 13G SEC filing, Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Ltd each hold 1,593,246 shares (5.08%), demonstrating collective institutional ownership. Additionally, Squarepoint Master Fund Limited holds 1,590,333 shares (5.07%), and Squarepoint Core Master Fund Limited holds 2,913 shares (0.01%), with all reported holdings reflecting shared voting and dispositive power.
LENZ Therapeutics (Nasdaq:LENZ) - Stock Analysis
This Simply Wall St analysis of LENZ Therapeutics (Nasdaq:LENZ) highlights the company's valuation, growth prospects, and financial health. The stock is currently trading significantly below fair value estimates, with revenue projected to grow substantially, yet the company remains unprofitable. Recent news includes insider stock purchases, analyst EPS revisions, and updates on its presbyopia treatment, VIZZ.
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares
LENZ Therapeutics President Evert Schimmelpennink recently increased his stake in the company by 57%, purchasing US$251k worth of shares at US$8.95 each. This significant insider buying activity, along with other insider purchases over the last year, indicates optimism about the company's future, despite its recent losses. Insiders now own about 2.5% of the company's shares.
Director at LENZ Therapeutics (LENZ) buys 5,592 shares in open-market trade
LENZ Therapeutics director George Jeffrey P. has reported an open-market purchase of 5,592 shares of common stock on March 27, 2026. The shares were acquired at a weighted average price of $8.9217, within a range of $8.80 to $9.12 per share, totaling approximately $50,000. Following this transaction, Mr. P. now directly holds 5,592 shares of LENZ common stock.
